

DOCKET NO.: ISIS-5582

Application No.: 10/510,667


PATENT

Restriction Requirement mailed: September 1, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:**What is Claimed is:**


1. (currently amended) An oligomeric compound having the formula:



wherein:

each Bx is, independently, a heterocyclic base moiety;

~~J1, J3 and each J2 is, independently, hydrogen~~ T₁ and T₂ are each independently, hydroxyl, a protected hydroxyl, an oligonucleotide, an oligonucleoside or a modified phosphate group having the structure formula:



wherein

one of Q₁ and Q₂ is S and the other of Q₁ and Q₂ is O;

Q₃ is OH or CH₃;

R₁, R₃ and each R₂ is, independently, hydrogen, hydroxyl, a sugar substituent group, a protected sugar substituent group or said modified phosphate group;

DOCKET NO.: ISIS-5582

Application No.: 10/510,667

PATENT

Restriction Requirement mailed: September 1, 2006

~~each T₁ and T₂ is, independently, hydroxyl, a protected hydroxyl, an oligonucleotide, an oligonucleoside or said modified phosphate group;~~

each X₁ and X₂ is, independently, O or S wherein at least one X₁ is S;

n is from 3 to 48; and

wherein at least one of T₁ or T₂ is said modified phosphate group.

2. (original) The oligomeric compound of claim 1 wherein Q₁ is S.

3. (original) The oligomeric compound of claim 1 wherein Q₂ is S.

4. (original) The oligomeric compound of claim 1 wherein Q₃ is CH₃.

Claims 5-10 (canceled)

11. (original) The oligomeric compound of claim 1 wherein R₁, R₃ and each R₂ is hydrogen.

12. (original) The oligomeric compound of claim 1 wherein R₁, R₃ and each R₂ is hydroxyl.

13. (currently amended) The oligomeric compound of claim 1 wherein R₁, R₃ and each R₂ is, independently, hydrogen, hydroxyl, a sugar substituent group or a protected sugar substituent group.

14. (original) The oligomeric compound of claim 1 wherein at least one of R₁, R₂ or R₃ is an optionally protected sugar substituent group.

15. (original) The oligomeric compound of claim 1 wherein each X₂ is S.

16. (original) The oligomeric compound of claim 1 wherein each heterocyclic base moiety is, independently, adenine, cytosine, 5-methylcytosine, thymine, uracil, guanine or 2-aminoadenine.

DOCKET NO.: ISIS-5582

Application No.: 10/510,667

PATENT

Restriction Requirement mailed: September 1, 2006

17. (original) The oligomeric compound of claim 1 wherein n is from about 8 to about 30.
18. (original) The oligomeric compound of claim 1 wherein n is from about 15 to 25.
19. (withdrawn) A method of treating an organism having a disease characterized by the undesired production of a protein comprising contacting the organism with an oligomeric compound of claim 1.
20. (original) A pharmaceutical composition comprising:
a pharmaceutically effective amount of an oligomeric compound of claim 1; and
a pharmaceutically acceptable diluent or carrier.
21. (withdrawn) A method of modifying *in vitro* a nucleic acid, comprising contacting a test solution containing RNase H and said nucleic acid with an oligomeric compound of claim 1.
22. (withdrawn) A method of concurrently enhancing hybridization and RNase H activation in a organism comprising contacting the organism with an oligomeric compound of claim 1.
23. (withdrawn) A method comprising contacting a cell with an oligomeric compound of claim 1.

Claims 24-41 (canceled)